The use of Impella RP is safe, feasible and provides a hemodynamic benefit in patients with right ventricular failure.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
30
Henry Ford Hospital
Detroit, Michigan, United States
RECRUITINGAlbert Einstein Medical Center
Philadelphia, Pennsylvania, United States
RECRUITINGPrimary Benefit Endpoint
Survival at 30 days or hospital discharge whichever is longer post device explant or to the next therapy, including transplant, bridge to transplant or destination therapy with FDA approved surgical VAD (Ventricular Assit Device).
Time frame: 30 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.